- Home
- CCM vs BNR Comparison
CCM vs BNR Comparison
Compare CCM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- BNR
- Stock Information
- Founded
- CCM 1997
- BNR 2014
- Country
- CCM China
- BNR China
- Employees
- CCM N/A
- BNR N/A
- Industry
- CCM Medical/Nursing Services
- BNR Medical Specialities
- Sector
- CCM Health Care
- BNR Health Care
- Exchange
- CCM Nasdaq
- BNR Nasdaq
- Market Cap
- CCM 33.3M
- BNR 38.3M
- IPO Year
- CCM 2009
- BNR 2020
- Fundamental
- Price
- CCM $5.40
- BNR $4.68
- Analyst Decision
- CCM
- BNR
- Analyst Count
- CCM 0
- BNR 0
- Target Price
- CCM N/A
- BNR N/A
- AVG Volume (30 Days)
- CCM 1.9K
- BNR 17.4K
- Earning Date
- CCM 04-25-2025
- BNR 08-21-2025
- Dividend Yield
- CCM N/A
- BNR N/A
- EPS Growth
- CCM N/A
- BNR N/A
- EPS
- CCM N/A
- BNR N/A
- Revenue
- CCM $52,603,198.00
- BNR $72,112,038.00
- Revenue This Year
- CCM N/A
- BNR $136.32
- Revenue Next Year
- CCM N/A
- BNR N/A
- P/E Ratio
- CCM N/A
- BNR N/A
- Revenue Growth
- CCM N/A
- BNR 0.53
- 52 Week Low
- CCM $3.80
- BNR $2.18
- 52 Week High
- CCM $10.50
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- CCM 42.16
- BNR 69.57
- Support Level
- CCM $5.20
- BNR $4.47
- Resistance Level
- CCM $7.15
- BNR $4.96
- Average True Range (ATR)
- CCM 0.21
- BNR 0.25
- MACD
- CCM 0.04
- BNR 0.11
- Stochastic Oscillator
- CCM 10.26
- BNR 84.31
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.